검색어 : 통합검색[Chastain Jessica]
총 15건 중 15건 출력
, 2/2 페이지
-
11
- Author Correction: Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial
- Usmani, Saad Z.; Facon, Thierry; Hungria, Vania; Bahlis, Nizar J.; Venner, Christopher P.; Braunstein, Marc; Pour, Ludek; Martí , Josep M.; Basu, Supratik; Cohen, Yael C.; Matsumoto, Morio; Suzuki, Kenshi; Hulin, Cyrille; Grosicki, Sebastian; Legiec, Wojciech; Beksac, Meral; Maiolino, Angelo; Takamatsu, Hiroyuki; Perrot, Aurore; Turgut, Mehmet; Ahmadi, Tahamtan; Liu, Weiping; Wang, Jianping; Chastain, Katherine; Vermeulen, Jessica; Krevvata, Maria; Lopez-Masi, Lorena; Carey, Jodi; Rowe, Melissa; Carson, Robin; Zweegman, Sonja; ; (Nature medicine, v.31, 2025, pp.1366-1366)
-
12
- Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS trial
- Usmani, Saad Z.; Facon, Thierry; Hungria, Vania; Bahlis, Nizar J.; Venner, Christopher P.; Braunstein, Marc; Pour, Ludek; Martí , Josep M.; Basu, Supratik; Cohen, Yael C.; Matsumoto, Morio; Suzuki, Kenshi; Hulin, Cyrille; Grosicki, Sebastian; Legiec, Wojciech; Beksac, Meral; Maiolino, Angelo; Takamatsu, Hiroyuki; Perrot, Aurore; Turgut, Mehmet; Ahmadi, Tahamtan; Liu, Weiping; Wang, Jianping; Chastain, Katherine; Vermeulen, Jessica; Krevvata, Maria; Lopez-Masi, Lorena; Carey, Jodi; Rowe, Melissa; Carson, Robin; Zweegman, Sonja; ; (Nature medicine, v.31, 2025, pp.1195-1202)
-
13
- Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial
- Zweegman, Sonja; Facon, Thierry; Hungria, Vania; Bahlis, Nizar J.; Venner, Christopher P.; Braunstein, Marc; Pour, Ludě k; Marti Tutusaus, Josep; Basu, Supratik; Cohen, Yael C.; Matsumoto, Morio; Suzuki, Kenshi; Hulin, Cyrille; Grosicki, Sebastian; Legiec, Wojciech Maciej; Beksac, Meral; Maiolino, Angelo; Takamatsu, Hiroyuki; Perrot, Aurore; Turgut, Mehmet; Liu, Weiping; Wang, Jianping; Chastain, Katherine; Vermeulen, Jessica; Krevvata, Maria; Lopez-Masi, Lorena; Carey, Jodi; Rowe, Melissa; Carson, Robin; Usmani, Saad Z.; 1Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam, Netherlands; 2University of Lille, CHU Lille, Service des Maladies du Sang, Lille, France; 3Clinica Sã o Germano, Sã o Paulo, Brazil; 4Arnie Charbonneau Cancer Research Institute, University of Calgary, Calgary, Canada; 5Department of Medical Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Canada; 7Department of Medicine, Division of Oncology-Hematology, NYU Long Island School of Medicine, Perlmutter Cancer Center, NYU Langone Hospital-Long Island, Mineola, NY; 8University Hospital Brno, Brno, Czech Republic; 9Hospital Mú tua de Terrassa, Barcelona, Spain; 10Royal Wolverhampton NHS Trust and University of Wolverhampton, CRN West Midlands, NIHR, Wolverhampton, United Kingdom; 11Department of Hematology, Tel-Aviv Sourasky (Ichilov) Medical Center, and Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel; 12Department of Hematolog; (Blood, v.144, 2024, pp.362-362)
-
14
- Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study
- Saad Z. Usmani; Thierry Facon; Vania Hungria; Nizar J. Bahlis; Christopher P. Venner; Marc Braunstein; Ludek Pour; Josep M. Martí; Supratik Basu; Yael C. Cohen; Morio Matsumoto; Kenshi Suzuki; Cyrille Hulin; Sebastian Grosicki; Wojciech Legiec; Meral Beksac; Angelo Maiolino; Hiroyuki Takamatsu; Aurore Perrot; Mehmet Turgut; Tahamtan Ahmadi; Weiping Liu; Jianping Wang; Katherine Chastain; Jessica Vermeulen; Maria Krevvata; Lorena Lopez-Masi; Jodi Carey; Melissa Rowe; Robin Carson; ; (Nature Medicine, v., 2025, )
-
15
- The Economic Impact of Levothyroxine Dose Adjustments: the CONTROL HE Study
- Ernst, Frank R.; Barr, Peri; Elmor, Riad; Sandulli, Walter; Thevathasan, Lionel; Sterman, Arnold B.; Goldenberg, Jessica; Vora, Kevin; Health Economics and Outcomes Research, Indegene, Inc., 222 Chastain Meadows Court, Suite 300, Kennesaw, GA 30144 USA; Health Economics and Outcomes Research, Indegene, Inc., 222 Chastain Meadows Court, Suite 300, Kennesaw, GA 30144 USA; Health Economics and Outcomes Research, Indegene, Inc., 222 Chastain Meadows Court, Suite 300, Kennesaw, GA 30144 USA; Akrimax Pharmaceuticals, LLC, Cranford, NJ USA; LT Associates Ltd, Paris, France; Arnold Sterman, MD, LLC, Morristown, NJ USA; Akrimax Pharmaceuticals, LLC, Cranford, NJ USA; Akrimax Pharmaceuticals, LLC, Cranford, NJ USA; (Clinical drug investigation, v.37, 2017, pp.71-83)
12
QUICK MENU
